JP2007503388A - マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 - Google Patents
マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 Download PDFInfo
- Publication number
- JP2007503388A JP2007503388A JP2006523903A JP2006523903A JP2007503388A JP 2007503388 A JP2007503388 A JP 2007503388A JP 2006523903 A JP2006523903 A JP 2006523903A JP 2006523903 A JP2006523903 A JP 2006523903A JP 2007503388 A JP2007503388 A JP 2007503388A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound
- group
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(CCI=C)(CN(c(nccc1)c1C(N(CC1)CCN1C(c1ccc[s]1)=O)=C1C#N)C1=O)*=C Chemical compound CC(CCI=C)(CN(c(nccc1)c1C(N(CC1)CCN1C(c1ccc[s]1)=O)=C1C#N)C1=O)*=C 0.000 description 11
- ZRSYMSALNHSZJI-UQQQWYQISA-N CCCC/C(/C(c1ccc[s]1)=O)=C/CCC(C)C(c1c(N2CCCCC=C)nccc1)=C(C(OCCC)=O)C2=O Chemical compound CCCC/C(/C(c1ccc[s]1)=O)=C/CCC(C)C(c1c(N2CCCCC=C)nccc1)=C(C(OCCC)=O)C2=O ZRSYMSALNHSZJI-UQQQWYQISA-N 0.000 description 1
- HDMNHDBVYIPLLY-UHFFFAOYSA-N CCOC(C(C(N(Cc1cccc(F)c1)c1c2cccn1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O)=O Chemical compound CCOC(C(C(N(Cc1cccc(F)c1)c1c2cccn1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O)=O HDMNHDBVYIPLLY-UHFFFAOYSA-N 0.000 description 1
- MVUVCDJPCFBGQH-UHFFFAOYSA-N CCOC(C(C(N(Cc1ccccc1)c1c2cccn1)=O)=C2Cl)=O Chemical compound CCOC(C(C(N(Cc1ccccc1)c1c2cccn1)=O)=C2Cl)=O MVUVCDJPCFBGQH-UHFFFAOYSA-N 0.000 description 1
- FLQAWRURJJNMDF-UHFFFAOYSA-N CCOC(C(C(N(Cc1ccccc1)c1c2cccn1)=O)=C2N1CCNCC1)=O Chemical compound CCOC(C(C(N(Cc1ccccc1)c1c2cccn1)=O)=C2N1CCNCC1)=O FLQAWRURJJNMDF-UHFFFAOYSA-N 0.000 description 1
- FWRVSXNYEKUWBL-UHFFFAOYSA-N CCOC(C(C(Nc1c2cccn1)=O)=C2Cl)=O Chemical compound CCOC(C(C(Nc1c2cccn1)=O)=C2Cl)=O FWRVSXNYEKUWBL-UHFFFAOYSA-N 0.000 description 1
- RPBUDWNKJBFNST-UHFFFAOYSA-N Cc(cc1)nc(C(Cc(cc2)ccc2F)C2)c1C(N1CCC(C(c3ccc[s]3)=O)=CCC1)=C(C(OCO)=O)C2=O Chemical compound Cc(cc1)nc(C(Cc(cc2)ccc2F)C2)c1C(N1CCC(C(c3ccc[s]3)=O)=CCC1)=C(C(OCO)=O)C2=O RPBUDWNKJBFNST-UHFFFAOYSA-N 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N Cc1ccc[o]1 Chemical compound Cc1ccc[o]1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- XQQBUAPQHNYYRS-UHFFFAOYSA-N Cc1ccc[s]1 Chemical compound Cc1ccc[s]1 XQQBUAPQHNYYRS-UHFFFAOYSA-N 0.000 description 1
- XKPGHFRZQDFMQP-UHFFFAOYSA-N N#CC(C(C=C(Cc1ccccc1F)Cc1c2cccn1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O Chemical compound N#CC(C(C=C(Cc1ccccc1F)Cc1c2cccn1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O XKPGHFRZQDFMQP-UHFFFAOYSA-N 0.000 description 1
- ZCGOHAYAKHIXSK-UHFFFAOYSA-N N#CC(C(N(Cc1ccccc1)c1c2cccn1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O Chemical compound N#CC(C(N(Cc1ccccc1)c1c2cccn1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O ZCGOHAYAKHIXSK-UHFFFAOYSA-N 0.000 description 1
- XXLWNPNRESZYGF-UHFFFAOYSA-N N#Cc1ccc(CN(c(nccc2)c2C(N(CC2)CCN2C(c2ccc[s]2)=O)=C2C#N)C2=O)cc1 Chemical compound N#Cc1ccc(CN(c(nccc2)c2C(N(CC2)CCN2C(c2ccc[s]2)=O)=C2C#N)C2=O)cc1 XXLWNPNRESZYGF-UHFFFAOYSA-N 0.000 description 1
- RAZJGTGKWULDIZ-UHFFFAOYSA-N NC(C(N1Cc2ccccc2)=O)=C(C(CCCC2)CCN2C(c2ccc[s]2)=O)c2c1nccc2 Chemical compound NC(C(N1Cc2ccccc2)=O)=C(C(CCCC2)CCN2C(c2ccc[s]2)=O)c2c1nccc2 RAZJGTGKWULDIZ-UHFFFAOYSA-N 0.000 description 1
- SMQYAJPRSXGWCI-UHFFFAOYSA-N O=C(c1ccc[s]1)N(CC1)CCN1C(c1c(N2Cc3ccccc3)nccc1)=C(C(OCN1CC1)=O)C2=O Chemical compound O=C(c1ccc[s]1)N(CC1)CCN1C(c1c(N2Cc3ccccc3)nccc1)=C(C(OCN1CC1)=O)C2=O SMQYAJPRSXGWCI-UHFFFAOYSA-N 0.000 description 1
- KUKGMDPEGDZCTL-UHFFFAOYSA-N O=C(c1ccc[s]1)N1CCNCC1 Chemical compound O=C(c1ccc[s]1)N1CCNCC1 KUKGMDPEGDZCTL-UHFFFAOYSA-N 0.000 description 1
- MJNQZBQPHJDFQU-UHFFFAOYSA-N [O-][N+](C(C(N(Cc1ccccc1)c1c2cccn1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O)=O Chemical compound [O-][N+](C(C(N(Cc1ccccc1)c1c2cccn1)=O)=C2N(CC1)CCN1C(c1ccc[s]1)=O)=O MJNQZBQPHJDFQU-UHFFFAOYSA-N 0.000 description 1
- UZDMCGSPIUJRMT-UHFFFAOYSA-N [O-][N+](C(C(N1Cc2ccccc2)=O)=C(C2[IH]C2)c2c1nccc2)=O Chemical compound [O-][N+](C(C(N1Cc2ccccc2)=O)=C(C2[IH]C2)c2c1nccc2)=O UZDMCGSPIUJRMT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49744303P | 2003-08-22 | 2003-08-22 | |
PCT/US2004/025683 WO2005021546A1 (en) | 2003-08-22 | 2004-08-09 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007503388A true JP2007503388A (ja) | 2007-02-22 |
JP2007503388A5 JP2007503388A5 (ko) | 2007-09-27 |
Family
ID=34272569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006523903A Pending JP2007503388A (ja) | 2003-08-22 | 2004-08-09 | マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20050124604A1 (ko) |
EP (1) | EP1656376A1 (ko) |
JP (1) | JP2007503388A (ko) |
CN (1) | CN1839133A (ko) |
AR (1) | AR045471A1 (ko) |
AU (1) | AU2004268941A1 (ko) |
BR (1) | BRPI0413695A (ko) |
CA (1) | CA2531506A1 (ko) |
MX (1) | MXJL06000006A (ko) |
PE (1) | PE20051112A1 (ko) |
TW (1) | TW200524928A (ko) |
UY (1) | UY28483A1 (ko) |
WO (1) | WO2005021546A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013536873A (ja) * | 2010-09-06 | 2013-09-26 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス,チャイニーズ アカデミー オブ サイエンスィズ | アミド化合物 |
JP2021526133A (ja) * | 2018-06-11 | 2021-09-30 | アムジエン・インコーポレーテツド | がんを処置するためのkras g12c阻害剤 |
JP2021528469A (ja) * | 2018-06-27 | 2021-10-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | T細胞アクティベーターとして有用なナフチリジノン化合物 |
JP2021529191A (ja) * | 2018-06-27 | 2021-10-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | T細胞アクティベーターとして有用な置換ナフチリジノン化合物 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140679A (en) * | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
CA2600175A1 (en) * | 2005-03-24 | 2006-03-20 | Avanir Pharmaceuticals | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
AU2007334323B2 (en) | 2006-12-18 | 2011-03-10 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
EP2097416B1 (en) | 2006-12-18 | 2012-09-12 | Amgen, Inc | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
JP2010524942A (ja) | 2007-04-18 | 2010-07-22 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン |
US7569726B2 (en) | 2007-04-18 | 2009-08-04 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
CA2685219C (en) | 2007-05-04 | 2012-06-19 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
WO2008137060A1 (en) | 2007-05-04 | 2008-11-13 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
WO2011056566A2 (en) * | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
US9133164B2 (en) * | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
CN103360388B (zh) * | 2012-04-10 | 2017-11-14 | 江苏先声药业有限公司 | 5‑氨基‑1,4‑二氢‑1,8‑萘啶衍生物及其药物组合物和用途 |
US9617212B2 (en) | 2013-12-17 | 2017-04-11 | Controlled Chemicals, Inc. | Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors |
KR102592246B1 (ko) | 2016-12-22 | 2023-10-23 | 암젠 인크 | 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
EP4141005B1 (en) | 2017-09-08 | 2024-04-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
CN107556309B (zh) * | 2017-09-11 | 2020-12-01 | 浙江永宁药业股份有限公司 | 多取代四氢萘啶类化合物的药物用途及其制备方法 |
AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MX2020011907A (es) | 2018-05-10 | 2021-01-29 | Amgen Inc | Inhibidores de kras g12c para el tratamiento de cancer. |
ES2938987T3 (es) | 2018-06-01 | 2023-04-18 | Amgen Inc | Inhibidores de KRAS G12c y métodos de uso de los mismos |
US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
EP3883565A1 (en) | 2018-11-19 | 2021-09-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
TWI816026B (zh) * | 2019-03-08 | 2023-09-21 | 大陸商藥捷安康(南京)科技股份有限公司 | 磷酸二酯酶抑制劑的用途和藥盒 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
US11236091B2 (en) | 2019-05-21 | 2022-02-01 | Amgen Inc. | Solid state forms |
AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
CA3196620A1 (en) | 2020-10-05 | 2022-04-14 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
EP4232027A1 (en) * | 2020-10-26 | 2023-08-30 | Yale University | Macrophage migration inhibitory factor inhibitors, and methods of making and using same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002058695A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
WO2002094203A2 (en) * | 2001-05-24 | 2002-11-28 | Avanir Pharmaceuticals | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
JP2003081946A (ja) * | 2001-07-03 | 2003-03-19 | Otsuka Pharmaceut Factory Inc | ナフチリジンおよびキノリン誘導体 |
JP2003512353A (ja) * | 1999-10-19 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
WO2003066630A2 (en) * | 2002-02-07 | 2003-08-14 | Amgen Inc. | Quinolinone derivatives for treating cell proliferation related disorders |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4324893A (en) * | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
US4299814A (en) * | 1979-05-25 | 1981-11-10 | Monsanto Company | Radioimmunoassay of MIF |
US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
HU200794B (en) * | 1984-02-22 | 1990-08-28 | Wellcome Found | Process for expressing malaria antigenes |
US5733524A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5801200A (en) * | 1984-03-19 | 1998-09-01 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
US5700447A (en) * | 1992-05-21 | 1997-12-23 | The Picowder Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5733933A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
AU592753B2 (en) | 1984-05-24 | 1990-01-25 | Ciba-Geigy Ag | Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications |
US4708937A (en) * | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8602626D0 (en) * | 1986-02-04 | 1986-03-12 | Ciba Geigy Ag | Neurite-promoting factor |
DE3789413T2 (de) | 1986-10-03 | 1994-07-28 | Ciba Geigy Ag | Lymphokin-ähnliche Peptide. |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FI82144C (fi) * | 1989-03-22 | 1991-01-10 | Wallac Oy | Foerfarande foer samtidig bestaemning av flera ligander. |
GB8915414D0 (en) * | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
US5328990A (en) | 1991-04-26 | 1994-07-12 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation of macrophage migration inhibition factor from ocular lens |
US5352660A (en) * | 1991-10-31 | 1994-10-04 | Mount Sinai Hospital Corporation | Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
ATE474597T1 (de) | 1993-05-17 | 2010-08-15 | Cytokine Pharmasciences Inc | Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt |
US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
US5650295A (en) * | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
US6420188B1 (en) * | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
JP2000512737A (ja) | 1996-04-18 | 2000-09-26 | アリアッド ファーマスーティカルズ,インク. | 試験管内蛍光偏光検定法 |
US5883224A (en) | 1996-04-19 | 1999-03-16 | Cytokine Sciences, Inc. | Characterization of transfer factors and methods of use |
JPH1171351A (ja) * | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
US6413939B1 (en) * | 1997-10-31 | 2002-07-02 | The Picower Institute For Medical Research | Inducible phosphofructokinase and the Warburg effect |
DE69811724T2 (de) | 1997-12-05 | 2003-10-16 | Upjohn Co | Fluoreszenz-basierte hts-(high throughput screening)assayverfahren für proteinkinase und phosphatase |
EP1101106A4 (en) * | 1998-07-28 | 2006-05-03 | Bd Biosciences Systems And Rea | DEVICE AND METHOD FOR ANALYZING CELLULAR MOTILITY |
US6214343B1 (en) * | 1999-05-24 | 2001-04-10 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of necrotizing enterocolitis |
JP2003513065A (ja) * | 1999-10-29 | 2003-04-08 | ザ・ピコワー・インスティチュート・フォー・メディカル・リサーチ | Mifアンタゴニスト活性を有する化合物 |
CN1675154A (zh) * | 2002-06-07 | 2005-09-28 | 科蒂科股份有限公司 | 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物 |
TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
-
2004
- 2004-08-09 BR BRPI0413695-0A patent/BRPI0413695A/pt not_active IP Right Cessation
- 2004-08-09 MX MXJL06000006A patent/MXJL06000006A/es unknown
- 2004-08-09 CN CNA2004800241375A patent/CN1839133A/zh active Pending
- 2004-08-09 AU AU2004268941A patent/AU2004268941A1/en not_active Abandoned
- 2004-08-09 WO PCT/US2004/025683 patent/WO2005021546A1/en active Application Filing
- 2004-08-09 JP JP2006523903A patent/JP2007503388A/ja active Pending
- 2004-08-09 CA CA002531506A patent/CA2531506A1/en not_active Abandoned
- 2004-08-09 EP EP04780510A patent/EP1656376A1/en not_active Ceased
- 2004-08-17 US US10/920,031 patent/US20050124604A1/en not_active Abandoned
- 2004-08-18 TW TW093124762A patent/TW200524928A/zh unknown
- 2004-08-20 UY UY28483A patent/UY28483A1/es not_active Application Discontinuation
- 2004-08-20 AR ARP040102991A patent/AR045471A1/es not_active Application Discontinuation
- 2004-08-21 PE PE2004000808A patent/PE20051112A1/es not_active Application Discontinuation
-
2007
- 2007-03-16 US US11/687,601 patent/US7361760B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003512353A (ja) * | 1999-10-19 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
WO2002058695A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
WO2002094203A2 (en) * | 2001-05-24 | 2002-11-28 | Avanir Pharmaceuticals | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
JP2003081946A (ja) * | 2001-07-03 | 2003-03-19 | Otsuka Pharmaceut Factory Inc | ナフチリジンおよびキノリン誘導体 |
WO2003066630A2 (en) * | 2002-02-07 | 2003-08-14 | Amgen Inc. | Quinolinone derivatives for treating cell proliferation related disorders |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013536873A (ja) * | 2010-09-06 | 2013-09-26 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス,チャイニーズ アカデミー オブ サイエンスィズ | アミド化合物 |
US9238643B2 (en) | 2010-09-06 | 2016-01-19 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amide compounds |
JP2021526133A (ja) * | 2018-06-11 | 2021-09-30 | アムジエン・インコーポレーテツド | がんを処置するためのkras g12c阻害剤 |
JP7357644B2 (ja) | 2018-06-11 | 2023-10-06 | アムジエン・インコーポレーテツド | がんを処置するためのkras g12c阻害剤 |
JP2021528469A (ja) * | 2018-06-27 | 2021-10-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | T細胞アクティベーターとして有用なナフチリジノン化合物 |
JP2021529191A (ja) * | 2018-06-27 | 2021-10-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | T細胞アクティベーターとして有用な置換ナフチリジノン化合物 |
JP7373512B2 (ja) | 2018-06-27 | 2023-11-02 | ブリストル-マイヤーズ スクイブ カンパニー | T細胞アクティベーターとして有用なナフチリジノン化合物 |
JP7432532B2 (ja) | 2018-06-27 | 2024-02-16 | ブリストル-マイヤーズ スクイブ カンパニー | T細胞アクティベーターとして有用な置換ナフチリジノン化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1839133A (zh) | 2006-09-27 |
US20070191388A1 (en) | 2007-08-16 |
EP1656376A1 (en) | 2006-05-17 |
US7361760B2 (en) | 2008-04-22 |
UY28483A1 (es) | 2005-03-31 |
MXJL06000006A (es) | 2006-05-04 |
AU2004268941A1 (en) | 2005-03-10 |
US20050124604A1 (en) | 2005-06-09 |
PE20051112A1 (es) | 2006-02-03 |
TW200524928A (en) | 2005-08-01 |
CA2531506A1 (en) | 2005-03-10 |
AR045471A1 (es) | 2005-10-26 |
BRPI0413695A (pt) | 2006-10-24 |
WO2005021546A1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7361760B2 (en) | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | |
JP4346312B2 (ja) | マクロファージ遊走阻止因子インヒビターおよびそれを同定する方法 | |
US7312220B2 (en) | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | |
AU2002303906A1 (en) | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070807 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070807 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110420 |